ArticlePDF Available

Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol

Authors:
  • School of Pharmacy, Ein Kerem Campus, Hebrew University of Jerusalem

Abstract and Figures

Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti-inflammatory and anti-anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or orally as a purified product, a bell-shaped dose-response was observed, which limits its clinical use. In the present study, we have studied in mice the anti-inflammatory and anti-nociceptive activities of standardized plant extracts derived from the Cannabis sativa L., clone 202, which is highly enriched in CBD and hardly contains any psychoactive ingredients. In stark contrast to purified CBD, the clone 202 extract, when given either intraperitoneally or orally, provided a clear correlation between the anti-inflammatory and anti-nociceptive responses and the dose, with increasing responses upon increasing doses, which makes this plant medicine ideal for clinical uses. The clone 202 extract reduced zymosan-induced paw swelling and pain in mice, and prevented TNFα production in vivo. It is likely that other components in the extract synergize with CBD to achieve the desired anti-inflammatory action that may contribute to overcoming the bell-shaped dose-response of purified CBD. We therefore propose that Cannabis clone 202 (Avidekel) extract is superior over CBD for the treatment of inflammatory conditions.
Comparison of anti-inflammatory and anti-nociceptive effects of CBD and Cannabis clone 202 extract with the commercial drugs aspirin and tramadol. (a) Prevention of zymosan-induced swelling of hind paw. 1.5% zymosan in 40 μl was injected into the sub-planter surface of the right hind paw. Immediately thereafter, aspirin (50 mg/kg per os), tramadol (5 mg/kg i.p.), CBD (5 mg/kg i.p.) or Cannabis clone 202 extract (50 mg/kg i.p.) was given. The paw thickness indicative for paw swelling was measured 2, 6 and 24 hrs later. The paw thickness of untreated mice was 2.0-2.2 mm, which made the baseline of the graph. N = 5 for each time point of each treatment group. * p < 0.001 in comparison to control mice. p < 0.005 when comparing CBD and clone 202 extract with aspirin and tramadol; (b) Anti-pain effect of aspirin, tramadol, CBD and Cannabis clone 202 extract in mice treated as described in paragraph A. The hyperalgesia was measured by using the von Frey nociceptive filament assay. The higher the paw withdrawal threshold, the higher is the anti-nociceptive effect of the drug. N = 5 for each time point of each treatment group. The bars represent standard error. * p < 0.001 in comparison to control mice. p < 0.05 when comparing CBD and clone 202 extract with aspirin and tramadol; (c) The TNFα serum concentration at 24 hrs in mice that were treated as described in paragraph A. N = 5 for each treatment. The bars represent standard error. * p < 0.001 in comparison to control mice. p < 0.01 when comparing CBD and clone 202 extract with aspirin and tramadol.
… 
Content may be subject to copyright.
Pharmacology&Pharmacy,2015,6,7585
PublishedOnlineFebruary2015inSciRes.http://www.scirp.org/journal/pp
http://dx.doi.org/10.4236/pp.2015.62010
Howtocitethispaper:Gallily,R.,Yekhtin,Z.andHanuš,L.O.(2015)OvercomingtheBellShapedDoseResponseofCan
nabidiolbyUsingCannabisExtractEnrichedinCannabidiol.Pharmacology&Pharmacy,6,7585.
http://dx.doi.org/10.4236/pp.2015.62010
OvercomingtheBellShaped
DoseResponseofCannabidiol
byUsingCannabisExtractEnriched
inCannabidiol
RuthGallily1,ZhannahYekhtin1,LumírOndřejHanuš2
1TheLautenbergCenterforGeneralandTumorImmunology,TheHadassahMedicalSchool,TheHebrew
UniversityofJerusalem,Jerusalem,Israel
2DepartmentofMedicinalandNaturalProducts,InstituteforDrugResearch,TheHadassahMedicalSchool,
TheHebrewUniversityofJerusalem,Jerusalem,Israel
Email:ruthg@ekmd.huji.ac.il
Received12November2014;accepted7February2015;published10February2015
Copyright©2015byauthorsandScientificResearchPublishingInc.
ThisworkislicensedundertheCreativeCommonsAttributionInternationalLicense(CCBY).
http://creativecommons.org/licenses/by/4.0/
Abstract
Cannabidiol(CBD),amajorconstituentofCannabis,hasbeenshowntobeapowerfulantiin‐
flammatoryandantianxietydrug,withoutexertingapsychotropiceffect.However,whengiven
eitherintraperitoneallyororallyasapurifiedproduct,abellshapeddoseresponsewasobserved,
whichlimitsitsclinicaluse.Inthepresentstudy,wehavestudiedinmicetheantiinflammatory
andantinociceptiveactivitiesofstandardizedplantextractsderivedfromtheCannabissativaL.,
clone202,whichishighlyenrichedinCBDandhardlycontainsanypsychoactiveingredients.In
starkcontrasttopurifiedCBD,theclone202extract,whengiveneitherintraperitoneallyororally,
providedaclearcorrelationbetweentheantiinflammatoryandantinociceptiveresponsesand
thedose,withincreasingresponsesuponincreasingdoses,whichmakesthisplantmedicineideal
forclinicaluses.Theclone202extractreducedzymosaninducedpawswellingandpaininmice,
andpreventedTNFαproductioninvivo.Itislikelythatothercomponentsintheextractsynergize
withCBDtoachievethedesiredantiinflammatoryactionthatmaycontributetoovercomingthe
bellshapeddoseresponseofpurifiedCBD.WethereforeproposethatCannabisclone202(Avi
dekel)extractissuperioroverCBDforthetreatmentofinflammatoryconditions.
Keywords
CannabissativaL.Clone202,Cannabidiol,AntiInflammation,AntiNociceptive,TNFα
R.Gallilyetal.
76
1.Introduction
Inflammation and pain have accompanied human life for ages. Many anti-inflammation and anti-pain medica-
tions and various approaches have been employed through the centuries and in recent time. Many of used drugs,
however, impose severe side effects. Cannabis from various origins and species has been employed in various
forms as anti-pain agents for thousands of years [1]-[3]. One example is the legitimated drug Sativex® (Nabixi-
mols) that is used in the treatment of severe spasticity in patients with multiple sclerosis [4]. Two other drugs,
Marinol (Dronabinol) and Cesamet, have been approved for use in cancer-related anorexia-cachexia syndrome
as well as for nausea and vomiting [3]. But a major disadvantage of Cannabis phytomedicine is its psychoactive
effects due to the presence of 9-Tetrahydrocannabinol (THC).
Recently, a science-based approach is being conducted to specify the benefits of Cannabis and its many con-
stituents. A Cannabis plant contains hundreds of different chemicals with about 60 - 80 chemicals known as
cannabinoids [5]. The major Cannabis psychoactive molecule is the -tetrahydrocannabinol, known as THC,
which binds with high affinity (Ki = 3 - 5 nM) [6] to both the cannabinoid CB1 receptor expressed in the brain
and the CB2 receptor expressed on cells of the immune system [7]. Another major constituent is Cannabidiol
(CBD) which is devoid of psychotropic effects and binds only with very low affinity (Ki > 10 μM) [6] to the
CB1/CB2 receptors. The other cannabinoids are present in minute amounts. Stimulation of CB1 receptor is re-
sponsible for the Cannabis psychoactivity, while activation of the CB2 receptor leads to attenuated inflamma-
tion, decreased injury and accelerated regeneration in many disease states [7]. CBD has been shown to activate
central nervous system’s limbic and paralimbic regions, which can reduce autonomic arousal and feeling of an-
xiety [3]. This is in contrast to THC which can be anxiogenic [3]. CBD has also been shown to have anti-emetic,
anti-inflammatory and anti-psychotic effects [3]. Studies are looking for potential benefits of phytocannabinoids
in management of neuropathic pain, hypertension, post-stroke neuroprotection, multiple sclerosis, epilepsy and
cancer [3]. Doses up to 1500 mg per day as well as chronic use of CBD have been reported as being well toler-
ated by humans [3].
During the last 10 - 15 years, many studies have focused on the anti-inflammatory effects of purified CBD in
various animal models, including rheumatoid arthritis, diabetes type 1, inflammatory bowel disease and multiple
sclerosis [8]-[13]. These studies showed that purified CBD gives a bell-shaped dose-response curve. Healing
was only observed when CBD was given within a very limited dose range, whereas no beneficial effect was
achieved at either lower or higher doses. This trait of purified CBD imposes serious obstacles in planning human
and animal studies. The aim of the present study was to find a CBD source that could eliminate the bell-shaped
dose-response of purified CBD. We found that by using standardized plant extracts from the Cannabis clone 202
obtained from Tikun Olam, Israel, which is highly enriched in CBD and barely contains THC, a correlative anti-
inflammatory and anti-pain dose-response could be achieved when applied either intraperitoneally or orally in
an inflammatory mouse model.
2.MaterialandMethods
2.1.CBDandCannabisClone202(Avidekel)Extract
Purified CBD was purchased from THC Pharm. GmbH, Frankfurt, Germany. Cannabis sativa L. flowers from
the clone 202 (Avidekel) rich in CBD while low in any psychotropic constituents was supplied by Tikun Olam
Company (a government-approved farm growing medicinal Cannabis), Israel. CBD-enriched extract was pre-
pared from the flowers of Cannabis clone 202 grown under controlled temperature and light conditions. 100%
ethanol (20 ml) was added to the chopped Cannabis dry flowers (200 mg) for 24 - 48 hrs, with occasional shak-
ing at room temperature. Following filtration, samples were taken for analysis. Ethanol solutions of Cannabis
clone 202 extracts (10 mg/ml - 20 mg/ml) were kept at 20˚C in the dark. The extract was evaporated on Rota-
vapor (BÜCHI Labortechnik AG, Switzerland). For intraperitoneal injection, the dried Cannabis clone 202 ex-
tract was emulsified in a vehicle composed of ethanol:Cremophor:saline at a 1:1:18 ratio. Purified CBD was
emulsified in the same vehicle. For oral administration, the dried Cannabis clone 202 extract and the purified
CBD were dissolved in olive oil.
2.2.AnalysisoftheCannabisClone202ExtractbyThinLayerChromatography(TLC)
Cannabis clone 202 extract (1 μl) was separated on TLC Silica Gel 60 F254 aluminium sheets (Merck, Darm-
R.Gallilyetal.
77
stadt, Germany) using hexane:dioxane (4:1) as a solvent in a chamber of 13 × 9 × 12 cm. The separated com-
ponents were detected by spraying the plates with a freshly prepared solution of 0.5 g Fast Blue B (D9805,
Sigma) in acetone/water (9:1; v/v). Cannabinoids in the dried plant material predominately appeared as can-
nabinoid acids. The TLC analysis shows two major spots corresponding to the acid and neutral form of CBD,
respectively, with only a minor spot corresponding to the acid form of THC (Figure 1(a)).
2.3.AnalysisoftheCannabisClone202ExtractbyGasChromatographyandMass
Spectrophotometry(GC/MS)
For analysis of the composition of the ethanol extracts of medicinal Cannabis clone 202, the ethanol was eva-
porated and the resin dissolved in 20 ml of methanol and filtered through cotton in a capillary. The concentration
of the extract was adjusted to 1 mg/ml to which 50 μg internal standard (Tetracosane, Acros Organics, USA)
was added. One l of this sample was applied for the GC/MS analysis. The quantitative analysis of the samples
by GC/MS was performed in a Hewlett Packard G 1800B GCD system with a HP-5971 gas chromatograph with
electron ionization detector. The software used was GCD Plus ChemStation. The column used was SPB-5 (30 m
× 0.25 mm × 0.25 μm film thickness). Experimental conditions were: inlet, 250˚C; detector, 280˚C; splitless in-
jection/purge time, 1.0 min; initial temperature, 100˚C; initial time, 2.0 min; rate, 10˚C/min; final temperature,
280˚C. The helium flow rate was 1 ml/min. Calibration curve was made from 25.0 to 100 μg/ml Cannabidiol
(CBD), 9-Tetetrahydrocannabinol (THC) or Cannabinol (CBN) together with 50.0 μg/ml tetracosane as internal
standard. The cannabinoid composition of Cannabis clone 202 extract is presented in Figure 1(b), Figure 1(c)
and Table 1.
2.4.CommercialAntiNociceptiveandAntiInflammatoryDrugs
The non-steroid anti-inflammatory drug (NSAID) aspirin (acetylsalicylic acid) was purchased from Sigma and
dissolved in olive oil. Fifty mg of aspirin was given per os per kg in a volume of 40 μl. The opioid anti-noci-
ceptive Tramadol hydrochloride was obtained from Grunenthal and dissolved in saline. Five mg of Tramadol
was given per os per kg.
Figure 1. (a) TLC analysis of clone 202 extract. 1 l of the extract was run on TLC as de-
scribed in the Method section. CBD = Cannabidiol. CBDA = Cannabidiolic acid; (b) (c) GC/
MS chromatograms of an extract from Cannabis clone 202. (b) The full chromatogram. (c)
Magnification of weaker signals. Number keys: 1: Cannabidivarol (CBDV); 2: Cannabidiol
(CBD); 3: Cannabichromene (CBC); 4: 9-Tetrahydrocannabinol (9-THC); 5: Cannabigerol
(CBG); 6: Cannabinol (CBN); I.S.-Internal Standard (Tetracosane).
R.Gallilyetal.
78
Table 1. The percentage of main phytocannabinoids found in clone 202 extract
according to GC/MS analysis (see Figures 1(b)-(c)).
Phytocannabinoid Content
Cannabidiol (CBD) 17.9%
Δ9-Tetrahydrocannabinol (Δ9-THC) 1.1%
Cannabichromene (CBC) 1.1%
Cannabigerol (CBG) 0.2%
Cannabinol (CBN) Traces
Cannabidivarol (CBDV) Traces
As cannabinoid acids during injection to the GC/MS decarboxylate, the results are a total sum
of neutral cannabinoids and cannabinoid acids that have decarboxylated into neutral can-
nabinoids. The content is the mass fraction (% w/w) of the given constituent in the extract.
2.5.Animals
Six to eight week old female Sabra mice (Israel) were maintained in the SPF unit of the Hebrew University-
Hadassah Medical School, Jerusalem, Israel. The experimental protocols were approved by the Animal Care
Ethical Committee of the Hebrew University-Hadassah Medical School, Jerusalem, Israel. The animals were
maintained on standard pellet diet and water ad libitum. The animals were maintained at a constant temperature
(20˚C - 21˚C) and a 12 h light/dark cycle.
2.6.InductionofPawInflammationinMiceandTreatmentwithPurifiedCBDorClone
202Extract
To induce inflammation, 40 μl of 1.5% (w/v) zymosan A (Sigma) suspended in 0.9% saline was injected into the
sub-planter surface of the right hind paw of the mice. Immediately after zymosan injection, CBD or Cannabis
clone 202 extract was injected intraperitoneally (i.p.) or given orally. For intraperitoneal injection, these agents
were dissolved in 0.1 ml vehicle containing ethanol:Cremophore:saline at a ratio of 1:1:18. Control mice were
injected with the vehicle only. For per os administration, the agents were dissolved in olive oil, each mouse re-
ceiving 40 μl. Control mice got 40 μl olive oil. After 2, 6 and 24 hrs, paw swelling and pain perception were
measured. Serum TNFα titers were determined after 24 hrs. The effects of CBD and Cannabis clone 202 extract
were compared to those of aspirin (50 mg/kg per os) and tramadol (5 mg/kg, i.p.).
2.7.MeasurementofOedemaFormation
The paw swelling (thickness) was measured by calibrated calipers (0.01 mm), 2, 6 and 24 hrs following injec-
tions of zymosan alone or with CBD or Cannabis clone 202 extracts.
2.8.PainAssay
The hyperalgesia was evaluated by the paw withdrawal von Frey test at 2, 6, and 24 hrs following injections of
zymosan and/or the test compounds. In the von Frey nociceptive filament assay, von Frey calibrated monofila-
ment hairs of logarithmically incremental stiffness (0.008 - 300 g corresponding to 1.65 - 6.65 log of force). In
our study, only 1.4 - 60 g corresponding to 4.17 to 5.88 log of force was used, to test the mouse sensitivity to a
mechanical stimulus on the swollen paw. The measurements were performed in a quiet room. Before paw pain
measurements, the animals were held for 10 sec. The trained investigator applied the filament to the central area
of the hind paw with gradual increasing size. The test consisted of poking the middle of the hind paw to provoke
a flexion reflex followed by a clear flinch response after paw withdrawal. Each one of the von Frey filaments
was applied for approximately 3 - 4 s to induce the end-point reflex. The first testing was done by using the
force filament of 1.4 g. If there was no withdrawal response, the next higher stimulus was tried. The mechanical
threshold force (in grams (g)) was defined as the lowest force imposed by two von Frey monofilaments of vari-
ous sizes, required to produce a paw retraction. The untreated left hind paw served as a control.
R.Gallilyetal.
79
2.9.TumorNecrosisFactorα(TNFα)PlasmaLevels
Plasma levels of TNFα were measured using a mouse TNFα ELISA kit (R&D System), according to the manu-
facturer’s instructions.
2.10.StatisticalAnalysis
The results are presented as average ± standard error. Mice treated with CBD or Cannabis clone 202 extracts
were compared with control mice receiving the vehicle only. Statistical significance was calculated using the
ANOVA analysis of variance and Wilcoxon signed-rank test. Differences between the various doses of CBD
and clone 202 extracts were analyzed for significance using the repeated measures ANOVA procedure with
Post-Hoc test. All tests were 2-tailed and a p-value below 0.05 was considered statistically significant. A mini-
mum of three to four animals was used in each treatment group for each experiment unless otherwise stated.
Each experiment was performed at least three times. The graphs represent the average of all mice from the three
different experiments. Thus, each bar corresponds to the average of 10 - 12 mice for each treatment group, for
each time point, unless otherwise stated.
3.Results
3.1.EffectofCBDandCBDEnrichedClone202ExtractonInflammationandHyperalgesia
(PainSensation)
In this study we have used the well-accepted mouse model of zymosan-induced inflammation [14] to investigate
the anti-inflammatory and anti-nociceptive activities of Cannabis clone 202 extract versus purified CBD. The
extent of hind paw swelling was determined 2, 6 and 24 hrs following paw injection of 60 μg zymosan together
with either intraperitoneal injection or per os administration of various amounts of either purified CBD or Can-
nabis clone 202 extract, as indicated in the graphs (Figure 2, Figure 3). Following intraperitoneal injection of 1,
5, 25 and 50 mg/kg of purified CBD, a bell-shaped dose-response is observed (Figure 2(a)). The maximum in-
hibition of inflammation occurred after an injection of 5 mg/kg CBD with 50% and 57% inhibition after 6 and
24 hrs, respectively (p < 0.001), while a lower dose (1 mg/kg) being ineffective and higher doses (25 and 50
mg/kg) being less effective with 20% - 25% and 14% - 28% inhibition only, after 6 and 24 hrs, respectively
(Figure 2(a)). In accordance with these findings, the anti-nociceptive effect, as determined by the von Frey
monofilament assay, peaked at 5 mg/kg CBD (p < 0.001) (Figure 2(c)). The anti-nociceptive effect occurred
prior (2 hrs) to inhibition of swelling (6 hrs), and peaked at 6 hrs. Higher concentrations of CBD had less an-
ti-nociceptive effects (Figure 2(c)), again getting a bell-shaped dose-response. However, when clone 202 extract
was used, a correlative dose-response was observed with increased inhibition of inflammation upon increased
doses of the extract, reaching 43% and 64% inhibition at 25 mg and 50 mg, respectively, after 24 hrs (p < 0.001)
(Figure 2(b)). These two dosages of clone 202 extract also showed strong anti-nociceptive effects after 6 and 24
hrs (p < 0.001) (Figure 2(d)). Although the anti-inflammatory effect of clone 202 extract was higher at 50
mg/kg than at 25 mg/kg with a p = 0.001, the anti-nociceptive effect was only slightly higher (p = 0.01), sug-
gesting that a plateau has been reached. The clone 202 extract was more efficient for alleviating the pain than
CBD (p = 0.01) (Figure 2(d) versus Figure 2(c)).
When CBD or Cannabis clone 202 extract was given orally, a similar response was observed. Namely, CBD
gives a bell-shaped dose-response with an optimal inhibitory effect at 25 mg/kg (p < 0.001) (Figure 3(a) and
Figure 3(c)), whereas Cannabis clone 202 extract provides a correlative dose-response curve with a maximum
effect on swelling and pain relief at 50 and 150 mg/kg, respectively (p < 0.001) (Figure 3(b) and Figure 3(d)).
Significant pain relief was already obtained with an oral clone 202 extract dose of 50 mg/kg (Figure 3(d)) that
corresponds to about 10 mg/kg CBD (Table 1), while 25 mg/kg of purified CBD was needed to achieve the
same effect (Figure 3(c)). This suggests for a better usage of clone 202 extract.
It should be noted that agents taken per os need to go through the enterohepatic route prior to exerting their
effects, where the absorption rate and first-pass liver metabolism affect the blood drug level [15]. This may ex-
plain the higher doses required and the delayed response in comparison with the parenteral route, where the
agents are immediately available for the blood circulation. The anti-inflammatory and anti-nociceptive effects
peak at 6 hrs, which accords with the pharmacokinetics and pharmacodynamics of cannabinoids described by
Grotenhermen [15].
R.Gallilyetal.
80
Figure 2. Anti-inflammatory and anti-nociceptive effects of intraperitoneally injected CBD and CBD-
enriched clone 202 extract. (a) (b) Prevention of zymosan-induced swelling of hind paw. 1.5% zymo-
san in 40 μl was injected into the sub-planter surface of the right hind paw. Immediately thereafter,
CBD (a) or Cannabis clone 202 extract (b) was injected intraperitoneally. The paw thickness indica-
tive for paw swelling was measured 2, 6 and 24 hrs thereafter. The paw thickness of untreated mice
was 2.0 - 2.2 mm, which made the baseline of the graph. N = 12 for each time point. *p < 0.001 com-
pared to control mice. p < 0.001 for 50 mg/kg vs 25 mg/kg of clone 202 extract at 24 hrs; (c) (d) Anti-
pain effect of CBD (c) and Cannabis clone 202 extract (d). The hyperalgesia was measured by using
the von Frey nociceptive filament assay. The higher the paw withdrawal threshold, the higher is the
anti-nociceptive effect of the drug. The experiments were repeated three times, each experiment with 4
mice in each treatment group. The graphs presents the average of all mice in the three experiments,
meaning that the N = 12 for each time point. The bars represent standard error. *p < 0.001 compared to
control mice. p < 0.01 for 50 mg/kg vs 25 mg/kg of clone 202 extract at 24 hrs. p < 0.01 for clone 202
extract vs CBD.
3.2.SuppressionofTNFαProductionbyCBDandClone202Extract
TNFα is a well-known pro-inflammatory cytokine secreted by activated macrophages upon inflammation that
has been shown to be involved in initiation and amplification of inflammatory processes that ultimately leads to
oedema [16]. Therefore, it was important to analyze the effect of CBD and clone 202 extracts on TNFα produc-
tion. To this end, mice sera were analyzed for TNFα concentration by ELISA 24 hrs after treatment with zymo-
san in the absence or presence of CBD or clone 202 extract. When comparing the TNFα sera level in mice 24
hrs after injection of increasing doses of purified CBD, a bell-shaped dose-response curve of TNFα production
was observed, with a maximum inhibitory effect (43%) achieved at 5 mg/kg (p < 0.001), while no inhibition was
observed at either lower (1 mg/kg) or higher (25 and 50 mg/kg) doses (Figure 4(a)). In contrast, following in-
jection of CBD-enriched clone 202 extract to mice, a clear dose dependent response was apparent. Increased in-
hibition of TNFα production (39%; 46% and 57%, respectively) was observed following injections with increas-
ing amounts of extract (5 mg/kg, 25 mg/kg and 50 mg/ml, respectively) with a p value less than 0.001 (Figure
4(b)). Already at 5 mg/kg did clone 202 extract lead to a strong reduction in TNFα production (Figure 4(b)),
R.Gallilyetal.
81
Figure 3. Anti-inflammatory and anti-nociceptive effects of CBD and CBD-enriched clone 202 ex-
tract administrated per os. (a) (b) Prevention of zymosan-induced swelling of hind paw. 1.5% zymo-
san in 40 μl was injected into the sub-planter surface of the right hind paw. Immediately thereafter,
CBD (a) or Cannabis clone 202 extract (b) was given per os dissolved in olive oil (40 μl). The paw
thickness indicative for paw swelling was measured 2, 6 and 24 hrs thereafter. The paw thickness of
untreated mice was 2.0 - 2.2 mm, which made the baseline of the graph. N = 12 for each time point.
*p < 0.001 in comparison to control mice. The anti-inflammatory effects of 25, 50, 100 and 150
mg/kg of clone 202 extract were similar; (c) (d) Anti-pain effect of CBD (c) and Cannabis clone 202
extract (d) when given orally. The hyperalgesia was measured by using the von Frey nociceptive fi-
lament assay. The higher the paw withdrawal threshold, the higher is the anti-nociceptive effect of the
drug. The experiments were repeated three times, each experiment with 4 mice in each treatment
group. The graphs presents the average of all mice in the three experiments, meaning that the N = 12
for each time point. The bars represent standard error. *p < 0.001 in comparison to control mice. p <
0.001 for 50 mg/kg clone 202 extract (containing 8.9 mg/kg CBD) vs 10 mg/kg purified CBD. p <
0.05 of 100 mg/kg and 150 mg/kg vs 50 mg/kg of clone 202 extract at 6 hrs, indicating a dose-
dependent effect.
even though this dose was insufficient in reducing paw swelling (Figure 2(b)) or relieve pain (Figure 2(d)). At
least 25 mg/kg extract, which corresponds to about 5 mg CBD, was required to achieve the anti-inflammatory
effect. These data show that TNFα secretion is more sensitive to inhibition by clone 202 extract, than paw swel-
ling and pain.
Similar to the results obtained with intraperitoneal injection, orally administrated CBD gave a bell-shape re-
sponse, with an optimal response using 25 mg/kg (p < 0.001), while higher or lower doses had less effect
(Figure 4(c)). In contrast, orally delivered clone 202 extract showed an increased inhibitory effect on TNFα
production with increased doses (Figure 4(d)). Already at 25 mg/kg an inhibition of 48% was achieved that in-
creased further to 66% when given 150 mg/kg clone 202 extract (Figure 4(d)). The inhibition of TNF produc-
tion was much stronger than the inhibitory effect on paw swelling of 27% - 35%.
R.Gallilyetal.
82
Figure 4. Prevention of zymosan-induced TNFα production by purified CBD and clone 202 extract.
(a) (b) Twenty four hours after injecting zymosan and an intraperitoneal dose of CBD (a) or clone
202 extract (b), or a per os dose of CBD (c) or clone 202 extract (d), the TNFα concentration in the
serum was determined by ELISA. The experiments were repeated three times, each experiment with
4 mice in each treatment group. The graphs presents the average of all mice in the three experiments,
meaning an N = 12 for each treatment. TNFα serum level of untreated mice was 15 pg/ml. The bars
represent standard error. *p < 0.001 in comparison to control mice. p < 0.01 when comparing clone
202 extract with purified CBD. p < 0.01 when comparing an increasing doses of clone 202 extract,
emphasizing a dose-dependent effect.
3.3.ComparisonofCBDandCannabisClone202ExtractwithCommercial
AntiNociceptiveandAntiInflammatoryDrugs
Since Cannabis clone 202 extract has profound anti-inflammatory and anti-nociceptive effects as described
above, it was important to compare its potency with commercial anti-nociceptive and anti-inflammatory drugs.
We chose to use tramadol, a strong atypical opioid analgesic drug, and aspirin, a well-known non-steroid anti-
inflammatory drug (NSAID) that is also a pain reliever. Immediately after zymosan injection, mice were treated
with aspirin (50 mg/kg per os), tramadol (5 mg/kg i.p.), CBD (5 mg/kg i.p.) or clone 202 extract (50 mg/kg i.p.).
While aspirin had a moderate effect on paw swelling (p < 0.001 at 6 h), tramadol barely had any effect (Figure
5(a)). Both CBD and clone 202 extract markedly prevented paw swelling to a much larger extent than aspirin (p
< 0.005) (Figure 5(a)). As expected, aspirin and tramadol had a strong anti-nociceptive effect that exceeded that
of CBD and clone 202 extract (p < 0.01) (Figure 5(b)). Aspirin, but not tramadol, showed a slight inhibitory ef-
fect on TNFα production, that was negligible in comparison to the strong inhibitory effect of CBD and clone
202 extract (p < 0.01) (Figure 5(c)). Thus, CBD and clone 202 extract are endowed with different traits than as-
pirin and tramadol, making them superior with respect to anti-inflammatory properties.
4.Discussion
In this manuscript we have observed different dose-response patterns when using purified CBD or plant extract
R.Gallilyetal.
83
Figure 5. Comparison of anti-inflammatory and anti-nociceptive effects of CBD and Cannabis
clone 202 extract with the commercial drugs aspirin and tramadol. (a) Prevention of zymo-
san-induced swelling of hind paw. 1.5% zymosan in 40 μl was injected into the sub-planter sur-
face of the right hind paw. Immediately thereafter, aspirin (50 mg/kg per os), tramadol (5 mg/kg
i.p.), CBD (5 mg/kg i.p.) or Cannabis clone 202 extract (50 mg/kg i.p.) was given. The paw
thickness indicative for paw swelling was measured 2, 6 and 24 hrs later. The paw thickness of
untreated mice was 2.0 - 2.2 mm, which made the baseline of the graph. N = 5 for each time
point of each treatment group. *p < 0.001 in comparison to control mice. p < 0.005 when com-
paring CBD and clone 202 extract with aspirin and tramadol; (b) Anti-pain effect of aspirin, tra-
madol, CBD and Cannabis clone 202 extract in mice treated as described in paragraph A. The
hyperalgesia was measured by using the von Frey nociceptive filament assay. The higher the paw
withdrawal threshold, the higher is the anti-nociceptive effect of the drug. N = 5 for each time
point of each treatment group. The bars represent standard error. *p < 0.001 in comparison to
control mice. p < 0.05 when comparing CBD and clone 202 extract with aspirin and tramadol; (c)
The TNFα serum concentration at 24 hrs in mice that were treated as described in paragraph A. N
= 5 for each treatment. The bars represent standard error. *p < 0.001 in comparison to control
mice. p < 0.01 when comparing CBD and clone 202 extract with aspirin and tramadol.
of the Cannabis sativa L. clone 202, which is highly enriched in CBD. Purified CBD showed a bell-shaped
dose-response, where a therapeutic response could only be achieved at a certain concentration. This narrow the-
rapeutic window makes it difficult to use CBD in the clinics as a single agent. Therefore, we sought for a better
preparation that can utilize the favorable therapeutic effects of CBD. We observed that plant extracts of the non-
psychotropic clone 202 could fit this aim. A dose-dependent response was observed on all three parameters
tested: namely, the extract prevented zymosan-induced paw oedema, zymosan-induced pain and zymosan-
induced TNFα production in mice, with an improved therapeutic effect upon increased dosages. Thus, the limi-
R.Gallilyetal.
84
tation with purified CBD could be overcome when presented together with other natural components of the plant.
Of note, TNFα secretion was more sensitive to clone 202 extract inhibition than paw swelling and pain.
Our finding that it is possible to get a correlative dose-response using Cannabis clone 202 extracts, makes it
possible to use it in many pathological conditions. We suggest that clone 202 extracts may be a suitable substi-
tute for the current used Cannabis strain in the clinics, especially taking into account that it does not have any
psychotropic adverse effects. Following the clinical improvement by the clone 202 extracts, more tedious ex-
periments with CBD might be planned.
Our findings that CBD in the presence of other plant constituents improve the dose-response are supported by
some recent reports showing that CBD in a standardized Cannabis sativa extract is more potent or efficacious
than pure CBD [17]-[19]. These research groups studied the anti-proliferative effect of CBD on tumor cells [17]
[19] and the inhibitory effect of CBD on bladder contractility [18]. The higher efficiency of plant extract might
be explained by additive or synergistic interactions between CBD and minor phytocannabinoids or non-canna-
binoids presented in the extracts. Other phytocannabinoids, including Tetrahydrocannabivarin, Cannabigerol and
Cannabichromene, exert additional effects of therapeutic interest [20]. A lot of research has been made to isolate
and characterize isolated single constituents of traditional herbal medicine to find their rationale for therapeutic
uses. However, our data together with those of others [21] provide legitimation to introduce a new generation of
phytopharmaceuticals to treat diseases that have hitherto been treated using synthetic drugs alone. The therapeu-
tic synergy observed with plant extracts results in the requirement for a lower amount of active components,
with consequent reduced adverse effects.
5.Conclusion
In conclusion, we recommend standardized plant extract of the Cannabis clone 202 for treatment of various in-
flammatory conditions.
Acknowledgements
The authors would like to thank Dr. Ronit Sionov for her valuable editorial assistance.
ConflictofInterest
Prof. Ruth Gallily has been a consultant for Tikun Olam since 2013, and has received a research grant during the
years 2012-2014 from Tikun Olam, Israel. There is no conflict of interest.
References
[1] Hazekamp, A., Ware, M.A., Muller-Vahl, K.R., Abrams, D. and Grotenhermen, F. (2013) The Medicinal Use of Can-
nabis and Cannabinoids—An International Cross-Sectional Survey on Administration Forms. Journal of Psychoactive
Drugs, 45, 199-210. http://dx.doi.org/10.1080/02791072.2013.805976
[2] Mechoulam, R. (2012) Cannabis—A Valuable Drug That Deserves Better Treatment. Mayo Clinic Proceedings, 87,
107-109. http://dx.doi.org/10.1016/j.mayocp.2011.12.002
[3] Greydanus, D.E., Hawver, E.K., Greydanus, M.M. and Merrick, J. (2013) Marijuana: Current Concepts. Frontiers in
Public Health, 1, 42. http://dx.doi.org/10.3389/fpubh.2013.00042
[4] Syed, Y.Y., McKeage, K. and Scott, L.J. (2014) Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of
Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. Drugs, 74, 563-578.
http://dx.doi.org/10.1007/s40265-014-0197-5
[5] Brenneisen, R. (2007) Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents. Marijuana and
the Cannabinoids, Chapter 2, 17-49. http://dx.doi.org/10.1007/978-1-59259-947-9_2
[6] Pertwee, R.G. (2008) The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: Delta9-Tetra-
hydrocannabinol, Cannabidiol and Delta9-Tetrahydrocannabivarin. British Journal of Pharmacology, 153, 199-215.
http://dx.doi.org/10.1038/sj.bjp.0707442
[7] Pacher, P. and Mechoulam, R. (2011) Is Lipid Signaling through Cannabinoid 2 Receptors Part of a Protective System?
Progress in Lipid Research, 50, 193-211. http://dx.doi.org/10.1016/j.plipres.2011.01.001
[8] Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R. and Feldmann, M. (2000)
The Nonpsychoactive Cannabis Constituent Cannabidiol Is an Oral Anti-Arthritic Therapeutic in Murine Collagen-In-
duced Arthritis. Proceedings of the National Academy of Sciences USA, 97, 9561-9566.
R.Gallilyetal.
85
http://dx.doi.org/10.1073/pnas.160105897
[9] Mechoulam, R., Peters, M., Murillo-Rodriguez, E. and Hanus, L.O. (2007) Cannabidiol—Recent Advances. Chemistry
& Biodiversity, 4, 1678-1692. http://dx.doi.org/10.1002/cbdv.200790147
[10] Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R. and Gallily, R. (2008) Cannabidiol Arrests Onset of
Autoimmune Diabetes in NOD Mice. Neuropharmacology, 54, 244-249.
http://dx.doi.org/10.1016/j.neuropharm.2007.06.029
[11] Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A. and Vogel, Z.
(2011) Cannabidiol Inhibits Pathogenic T Cells, Decreases Spinal Microglial Activation and Ameliorates Multiple
Sclerosis-Like Disease in C57BL/6 Mice. British Journal of Pharmacology, 163, 1507-1519.
http://dx.doi.org/10.1111/j.1476-5381.2011.01379.x
[12] Esposito, G., Filippis, D.D., Cirillo, C., Iuvone, T., Capoccia, E., Scuderi, C., Steardo, A., Cuomo, R. and Steardo, L.
(2013) Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. Phytotherapy Research, 27, 633-636.
http://dx.doi.org/10.1002/ptr.4781
[13] Jamontt, J.M., Molleman, A., Pertwee, R.G. and Parsons, M.E. (2010) The Effects of Delta-Tetrahydrocannabinol and
Cannabidiol Alone and in Combination on Damage, Inflammation and in Vitro Motility Disturbances in Rat Colitis.
British Journal of Pharmacology, 160, 712-723. http://dx.doi.org/10.1111/j.1476-5381.2010.00791.x
[14] Gadó, K. and Gigler, G. (1991) Zymosan Inflammation: A New Method Suitable for Evaluating New Anti-Inflamma-
tory Drugs. Agents and Actions, 32, 119-121. http://dx.doi.org/10.1007/BF01983335
[15] Grotenhermen, F. (2003) Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clinical Pharmacokinetics, 42,
327-360. http://dx.doi.org/10.2165/00003088-200342040-00003
[16] Rocha, A.C., Fernandes, E.S., Quintao, N.L., Campos, M.M. and Calixto, J.B. (2006) Relevance of Tumour Necrosis
Factor-Alpha for the Inflammatory and Nociceptive Responses Evoked by Carrageenan in the Mouse Paw. British
Journal of Pharmacology, 148, 688-695. http://dx.doi.org/10.1038/sj.bjp.0706775
[17] Romano, B., Borrelli, F., Pagano, E., Cascio, M.G., Pertwee, R.G. and Izzo, A.A. (2014) Inhibition of Colon Carcino-
genesis by a Standardized Cannabis Sativa Extract with High Content of Cannabidiol. Phytomedicine, 21, 631-639.
http://dx.doi.org/10.1016/j.phymed.2013.11.006
[18] Capasso, R., Aviello, G., Borrelli, F., Romano, B., Ferro, M., Castaldo, L., Montanaro, V., Altieri, V. and Izzo, A.A.
(2011) Inhibitory Effect of Standardized Cannabis Sativa Extract and Its Ingredient Cannabidiol on Rat and Human
Bladder Contractility. Urology, 77, 1006.e9-1006e15. http://dx.doi.org/10.1016/j.urology.2010.12.006
[19] De Petrocellis, L., Ligresti, A., Schiano Moriello, A., Iappelli, M., Verde, R., Stott, C.G., Cristino, L., Orlando, P. and
Di Marzo, V. (2013) Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth in Vitro and in Vivo: Pro-Apoptotic
Effects and Underlying Mechanisms. British Journal of Pharmacology, 168, 79-102.
http://dx.doi.org/10.1111/j.1476-5381.2012.02027.x
[20] Russo, E.B. (2011) Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects.
British Journal of Pharmacology, 163, 1344-1364. http://dx.doi.org/10.1111/j.1476-5381.2011.01238.x
[21] Wagner, H. and Ulrich-Merzenich, G. (2009) Synergy Research: Approaching a New Generation of Phytopharmaceu-
ticals. Phytomedicine, 16, 97-110. http://dx.doi.org/10.1016/j.phymed.2008.12.018
... CBGA for example reaches a high maximal concentration of 176.14 ± 21.1 μm in murine plasma with a single intraperitoneal (i.p.) injection of just 10 mg/kg, which is above the concentration needed to achieve the inhibition of SOCE. 31,52 Anderson et al. also showed that these acidic cannabinoids are absorbed into brain tissue and the type of vehicle can change the brain-plasma ratios, as they exhibit poor brain penetration in an oil vehicle as opposed to a Tween-based vehicle. This suggests that our lead compound, CBGA, can be used to target peripheral inflammation as well as inflammation in the central nervous system. ...
... 55 Moreover, Blasco-Benito et al. investigated this entourage effect by comparing pure cannabinoids and botanical extracts with corresponding concentrations of terpenes with standard chemotherapeutic drugs used in different breast cancer therapies. 52,55 Interestingly, the authors found that in all cases the botanical extract outperformed the pure cannabinoids in cell cultures but not in vivo and both the botanical extract and pure cannabinoids had no impact on standard chemotherapeutic therapies. 55 Our study investigated the potential entourage effect between our most potent cannabinoid, CBGA, in combination with one additional cannabinoid. ...
Article
Full-text available
Cannabis sativa has long been known to affect numerous biological activities. Although plant extracts, purified cannabinoids, or synthetic cannabinoid analogs have shown therapeutic potential in pain, inflammation, seizure disorders, appetite stimulation, muscle spasticity, and treatment of nausea/vomiting, the underlying mechanisms of action remain ill-defined. In this study we provide the first comprehensive overview of the effects of whole-plant Cannabis extracts and various pure cannabinoids on store-operated calcium (Ca2+) entry (SOCE) in several different immune cell lines. SOCE is one of the most significant Ca2+ influx mechanism in immune cells and it is critical for the activation of T lymphocytes, leading to the release of pro-inflammatory cytokines and mediating inflammation and T cell proliferation, key mechanisms for maintaining chronic pain. While the two major cannabinoids cannabidiol (CBD) and trans-Δ9-tetrahydrocannabinol (THC) were largely ineffective in inhibiting SOCE, we report for the first time that several minor cannabinoids, mainly the carboxylic acid derivatives and particularly the cannabigerolic acid (CBGA), demonstrated high potency against SOCE by blocking Calcium Release-Activated Calcium (CRAC) currents. Moreover, we show that this inhibition of SOCE resulted in a decrease of Nuclear Factor of Activated T-cells (NFAT) activation and Interleukin 2 (IL-2) production in human T lymphocytes. Taken together, these results indicate that cannabinoid-mediated inhibition of a pro-inflammatory target such as SOCE may at least partially explain the anti-inflammatory and analgesic effects of Cannabis.
... Takaidza et al. (2018b) also reported that the acetone extract of fresh T. violacea leaves had the highest antioxidant activity among eight Tulbaghia species. (Cravotto et al. 2010;Rasoanaivo et al. 2011;Gallily et al. 2015). It was shown that CBD together with other plant constituents improved the doseresponse and is supported by some recent reports showing that CBD in a standardized Cannabis sativa extract is more potent or efficacious than pure CBD (Gallily et al. 2015). ...
... (Cravotto et al. 2010;Rasoanaivo et al. 2011;Gallily et al. 2015). It was shown that CBD together with other plant constituents improved the doseresponse and is supported by some recent reports showing that CBD in a standardized Cannabis sativa extract is more potent or efficacious than pure CBD (Gallily et al. 2015). One of the advantages of herbal medicines is their multiplex composition. ...
Chapter
Integrating greeneries into the indoor dwelling environment boosts work performance and relieves stress to add to the overall psychological well-being especially in deserted urban settings. In addition to mental soothing, thermal regulation, air purification, aesthetics, public health, and comfort, the addition of plants to indoor settings may also contribute to the conservation of dwindling floral biodiversity. Despite authorities’ pledge for sustainable urban management, the status of indoor gardening has hitherto remained unexplored in the emerging megapolis of Bangladesh—Chattogram—the second largest urban center of the country. In addressing that gap, this study aims to explore the composition, diversity, and management of indoor plants in urban dwellings at Halishahar of Chattogram based on interviews on 48 households selected through multistage random sampling. Data from all selected households were collected by using a semi-structured questionnaire through physically visiting the households. Almost half of the households (48%) living at Halishahar had indoor plants in their dwellings. The study recorded a handsome 120 indoor plant species belonging to 108 genera from 60 families. While the diversity was in no way comparable to the tropical ecosystem of the country, in consideration of the strict set of requirements for plants to be suitable for an indoor setting, the diversity seemed excellent as evident from four diversity indices. Soil mixed with compost, sand, and surki at different ratios is used as potting media. Pests were identified as the major challenge in managing the indoor plants. Application of domestic manure with the potting media was common as a means to maintain the nutrient flow. Bruised tea leaf is the most frequently added nutrient supplement. Apart from the aesthetic values, urban dwellers from Halishahar reported the immense potential of indoor gardening in supplementing daily nutrition and in mitigating the impacts of climate change. The lessons from this study can be used in informed policymaking for the promotion of biodiversity conservation and other benefits from indoor greening among urban dwellers in Bangladesh.
... Takaidza et al. (2018b) also reported that the acetone extract of fresh T. violacea leaves had the highest antioxidant activity among eight Tulbaghia species. (Cravotto et al. 2010;Rasoanaivo et al. 2011;Gallily et al. 2015). It was shown that CBD together with other plant constituents improved the doseresponse and is supported by some recent reports showing that CBD in a standardized Cannabis sativa extract is more potent or efficacious than pure CBD (Gallily et al. 2015). ...
... (Cravotto et al. 2010;Rasoanaivo et al. 2011;Gallily et al. 2015). It was shown that CBD together with other plant constituents improved the doseresponse and is supported by some recent reports showing that CBD in a standardized Cannabis sativa extract is more potent or efficacious than pure CBD (Gallily et al. 2015). One of the advantages of herbal medicines is their multiplex composition. ...
Chapter
Permaculture has been known to intentionally integrate diversity into the design of farms and mimic natural landscapes. This approach is in contrast to the mainstream monocropping system in conventional agriculture. The objectives of the study were to identify what plant species are commonly cultivated in permaculture farms and determine its uses as narrated by farmers and practitioners. The researchers conducted a crop inventory in 12 permaculture sites in the Philippines from August to November in 2018. To survey a 1 ha sampling area, a modified belt transect method with alternating 20 m2 plots was employed for full enumeration of plant species in each plot. To determine uses, key informant interviews and focus group discussions were conducted among farm staff. A total of 215 plant species were identified with an average species richness of 46 per farm. A comparison of crop inventories revealed that Colocasia esculenta and Capsicum frutescens were the most commonly cultivated crops found in ten sites (83%). It is followed by Annona muricata (nine sites) and Bambusoideae (eight). Results revealed that the majority of crops found were cultivated for household consumption.
... Takaidza et al. (2018b) also reported that the acetone extract of fresh T. violacea leaves had the highest antioxidant activity among eight Tulbaghia species. (Cravotto et al. 2010;Rasoanaivo et al. 2011;Gallily et al. 2015). It was shown that CBD together with other plant constituents improved the doseresponse and is supported by some recent reports showing that CBD in a standardized Cannabis sativa extract is more potent or efficacious than pure CBD (Gallily et al. 2015). ...
... (Cravotto et al. 2010;Rasoanaivo et al. 2011;Gallily et al. 2015). It was shown that CBD together with other plant constituents improved the doseresponse and is supported by some recent reports showing that CBD in a standardized Cannabis sativa extract is more potent or efficacious than pure CBD (Gallily et al. 2015). One of the advantages of herbal medicines is their multiplex composition. ...
Chapter
Breeders need access to unique genetic variability to meet the growing demand for food while maintaining sustainable agricultural production with the impacts of climate change for generating high-quality nutritional food. Changes in climate and anthropogenic activities and a multitude of environmental influences pose severe threats to food supply and preservation of natural diversity. For example, unpredictable droughts, elevated temperature, and new diseases and pests threaten crop production. Thus, breeding with crop wild relatives (CWR) gives significant resilience to modern agricultural systems and the ability to help sustainably boosting agricultural productivity. As a result, numerous genotype screenings are necessary for broad adaptability, producing a segregating material through fast breeding or rapid generation to shorten the breeding cycle and improving genetic gain. In addition, CWR genomics generates data that support CWR’s usage to boost agricultural genetic diversity. QTL mapping, identifying of candidate genes by next-generation sequencing, gene-based marker development, or significant candidate gene pyramiding of stress-responsive loci in popular cultivar are required to maintain the sustainability of crop production. Thus, genomic data is useful for identifying and isolating novel and dominant alleles of genes from crop gene pools that are agronomically important, which can be used to generate improved crop cultivars. Hence, the natural allelic difference in candidate genes that influences major agronomic characteristics and crop development initiatives is being investigated via allele mining. Among the CWRs of economically important crops, the wild species of rice is essential to improve modern rice cultivars. The awareness of novel genetic and genomic approaches of rice genetic resources for efficient utilization is crucial. Further, their conservation status and availability have not been quantified globally. As a result, a joint effort is required to improve the conservation and accessibility of crop wild relatives for rice breeding. Keywords: Genomics of CWR, Crop improvement, Rice genetic resources
... It has been found to be effective in reducing anxiety (69), Parkinson's disease related symptoms (39), disruptive behavior, and other autism related symptoms (40). CBD has been also found to be effective as an anticonvulsant (41 (72,73). The difference in the average CMAI scores between groups only became significant at week 14, highlighting the importance of patience in the first few months of treatment based mainly on CBD. ...
Article
Full-text available
Background Almost 90% of patients with dementia suffer from some type of neurobehavioral symptom, and there are no approved medications to address these symptoms. Objective To evaluate the safety and efficacy of the medical cannabis oil “Avidekel” for the reduction of behavioral disturbances among patients with dementia. Materials and methods In this randomized, double-blind, single-cite, placebo-controlled trial conducted in Israel ( ClinicalTrials.gov : NCT03328676), patients aged at least 60, with a diagnosis of major neurocognitive disorder and associated behavioral disturbances were randomized 2:1 to receive either “Avidekel,” a broad-spectrum cannabis oil (30% cannabidiol and 1% tetrahydrocannabinol: 295 mg and 12.5 mg per ml, respectively; n = 40) or a placebo oil ( n = 20) three times a day for 16 weeks. The primary outcome was a decrease, as compared to baseline, of four or more points on the Cohen-Mansfield Agitation Inventory score by week 16. Results From 60 randomized patients [mean age, 79.4 years; 36 women (60.0%)], 52 (86.7%) completed the trial (all eight patients who discontinued treatment were from the investigational group). There was a statistically significant difference in the proportion of subjects who had a Cohen-Mansfield Agitation Inventory score reduction of ≥ 4 points at week 16: 24/40 (60.0%) and 6/20 (30.0%) for investigational and control groups, respectively (χ ² = 4.80, P = 0.03). There was a statistically significant difference in the proportion of subjects who had a Cohen-Mansfield Agitation Inventory score reduction of ≥ 8 points at week 16: 20/40 (50%) and 3/20 (15%), respectively (χ ² = 6.42, P = 0.011). The ANOVA repeated measures analysis demonstrated significantly more improvement in the investigational group compared to the control group at weeks 14 and 16 ( F = 3.18, P = 0.02). Treatment was mostly safe, with no significant differences in the occurrence of adverse events between the two groups. Conclusion In this randomized controlled trial, ‘Avidekel’ oil significantly reduced agitation over placebo in patients suffering from behavioral disturbances related to dementia, with non-serious side-effects. Further research is required with a larger sample size.
... 47 Further, research suggests that full-or broad-spectrum products, which have diverse profiles of cannabinoids and other compounds including terpenoids and flavonoids, may produce synergistic effects resulting in therapeutic response at lower doses with reduced risk of side effects relative to single compound, isolate products. [48][49][50] Minimizing the dosage of MC products to the lowest level necessary to achieve therapeutic benefit is particularly important given that a number of cannabinoids interact with cytochrome P450 enzymes, 51,52 and significant drug-drug interactions have been reported between cannabis use and other medications such as antidepressants. 53 Consumers should be aware of this potential issue and the impact MC use may have on other medications. ...
Article
Full-text available
Objective: Expanding access to legal cannabis has dovetailed with increased interest in medical cannabis (MC) use; however, there is a paucity of research examining MC use to alleviate menopause-related symptoms. This survey study assessed patterns of MC use in perimenopausal and postmenopausal individuals. Methods: Participants (perimenopausal, n = 131; postmenopausal, n = 127) completed assessments of menopause-related symptomatology and cannabis use, including modes of use, type of use, and menopause-related symptoms addressed by MC use. Results: Most participants reported current cannabis use (86.1%) and endorsed using MC for menopause-related symptoms (78.7%). The most common modes of use were smoking (84.3%) and edibles (78.3%), and the top menopause-related symptoms for MC use were sleep disturbance (67.4%) and mood/anxiety (46.1%). Relative to postmenopausal participants, perimenopausal participants reported significantly worse menopause-related symptomatology on the vasomotor and psychosocial subscales of the Menopause-Specific Quality of Life Questionnaire (Ps ≤ 0.04), including greater burden of anxiety (P = 0.01) and hot flash (P = 0.04) symptoms. In addition, perimenopausal participants reported higher incidence of depression (P = 0.03) and anxiety diagnoses (P < 0.01), as well as increased use of MC to treat menopause-related mood/anxiety symptoms relative to postmenopausal participants (P = 0.01). Conclusions: Results suggest that many individuals are currently using MC as an adjunctive treatment for menopause-related symptoms, particularly sleep disturbance and mood/anxiety. Future research should examine the impact of different MC use characteristics (e.g., cannabinoid profiles) on the efficacy of MC use for menopause-related symptoms. Increased severity and prevalence of mood and anxiety symptoms in perimenopausal participants suggest promising targets for clinical trials of cannabinoid-based therapies.
... Moreover, in some cases, the activity of a combination of phytomolecules was found to be superior over that of a single molecule. This was demonstrated in an in vivo study on inflammation, where treatment with CBD combined with cannabis extract overcame the bell-shaped dose-response of purified CBD, suggesting that components found in the extract synergize with CBD to achieve the desired anti-inflammatory action (Gallily et al., 2015). In addition, a phytocannabinoid formulation showed superior activity reducing lung inflammation over the cannabis-derived fraction in vitro. ...
Article
Full-text available
Inflammation often develops from acute, chronic, or auto-inflammatory disorders that can lead to compromised organ function. Cannabis (Cannabis sativa) has been used to treat inflammation for millennia, but its use in modern medicine is hampered by a lack of scientific knowledge. Previous studies report that cannabis extracts and inflorescence inhibit inflammatory responses in vitro and in pre-clinical and clinical trials. The endocannabinoid system (ECS) is a modulator of immune system activity, and dysregulation of this system is involved in various chronic inflammations. This system includes cannabinoid receptor types 1 and 2 (CB1 and CB2), arachidonic acid-derived endocannabinoids, and enzymes involved in endocannabinoid metabolism. Cannabis produces a large number of phytocannabinoids and numerous other biomolecules such as terpenes and flavonoids. In multiple experimental models, both in vitro and in vivo, several phytocannabinoids, including Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabigerol (CBG), exhibit activity against inflammation. These phytocannabinoids may bind to ECS and/or other receptors and ameliorate various inflammatory-related diseases by activating several signaling pathways. Synergy between phytocannabinoids, as well as between phytocannabinoids and terpenes, has been demonstrated. Cannabis activity can be improved by selecting the most active plant ingredients (API) while eliminating parts of the whole extract. Moreover, in the future cannabis components might be combined with pharmaceutical drugs to reduce inflammation.
Article
Cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), two of the primary constituents of cannabis, are used by some individuals to self-treat chronic pain. It is unclear whether the pain-relieving effects of CBD alone and in combination with THC are consistent across genders and among types of pain. The present study compared the effects of CBD and THC given alone and in combination in male and female rats with Complete Freund's adjuvant-induced inflammatory pain. After induction of hindpaw inflammation, vehicle, CBD (0.05-2.5 mg/kg), THC (0.05-2.0 mg/kg), or a CBD:THC combination (3:1, 1:1, or 1:3 dose ratio) was administered i.p. twice daily for three days. Then on day four, mechanical allodynia, thermal hyperalgesia, weight-bearing, and locomotor activity were assessed 0.5-4 h after administration of the same dose combination. Hindpaw edema and open field (anxiety-like) behaviors were measured thereafter. THC alone was anti-allodynic and anti-hyperalgesic, and decreased paw thickness, locomotion, and open field behaviors. CBD alone was anti-allodynic and anti-hyperalgesic. When combined with THC, CBD tended to decrease THC effects on pain-related behaviors and exacerbate THC-induced anxiety-like behaviors, particularly in females. These results suggest that at the doses tested, CBD-THC combinations may be less beneficial than THC alone for the treatment of chronic inflammatory pain. Perspective The present study compared CBD and THC effects alone and in combination in male and female rats with persistent inflammatory pain. This study could help clinicians who prescribe cannabis-based medicines for inflammatory pain conditions determine which cannabis constituents may be most beneficial.
Article
Full-text available
Substance use disorder (SUD) is a global public health concern that affects millions of people worldwide. Considering current research, addiction has been noted as the last stage of a chronic disease that may impair brain reward circuit responses and affects personal and social life. Treatments for SUD face challenges including availability and limited pharmacological response, often resulting in low retention of patients. A growing number of studies from the 'psychedelic renaissance' have highlighted the therapeutic potential of psychedelics for several psychiatric disorders, including SUD. In this non-systematic review we discuss past and current clinical and observational studies with classic (LSD, DMT, psilocybin and mescaline) and non-classic (ibogaine, ketamine, MDMA, salvinorin A and THC) psychedelics for the treatment of SUD published until December 2021. Although results are still inconclusive for LSD, DMT, mescaline, MDMA and Salvinorin A, in general, the literature presents moderate evidence on the controlled use of psilocybin and ketamine for Alcohol Use Disorder, ketamine for management of opiate and alcohol withdrawal, and THC preparations for reducing withdrawal symptoms in Cannabis and possibly in Opioid Use Disorder. Importantly, studies suggest that psychedelics should be more effective when employed as an adjunct therapy. Extensive research is warranted to further elucidate the role of psychedelics in the treatment of SUD.
Article
Full-text available
Marijuana (cannabis) remains a controversial drug in the twenty-first century. This paper considers current research on use of Cannabis sativa and its constituents such as the cannabinoids. Topics reviewed include prevalence of cannabis (pot) use, other drugs consumed with pot, the endocannabinoid system, use of medicinal marijuana, medical adverse effects of cannabis, and psychiatric adverse effects of cannabis use. Treatment of cannabis withdrawal and dependence is difficult and remains mainly based on psychological therapy; current research on pharmacologic management of problems related to cannabis consumption is also considered. The potential role of specific cannabinoids for medical benefit will be revealed as the twenty-first century matures. However, potential dangerous adverse effects from smoking marijuana are well known and should be clearly taught to a public that is often confused by a media-driven, though false message and promise of benign pot consumption.
Article
Full-text available
Cannabinoids, including tetrahydrocannabinol and cannabidiol, are the most important active constituents of the cannabis plant. Over recent years, cannabinoid-based medicines (CBMs) have become increasingly available to patients in many countries, both as pharmaceutical products and as herbal cannabis (marijuana). While there seems to be a demand for multiple cannabinoid-based therapeutic products, specifically for symptomatic amelioration in chronic diseases, therapeutic effects of different CBMs have only been directly compared in a few clinical studies. The survey presented here was performed by the International Association for Cannabinoid Medicines (IACM), and is meant to contribute to the understanding of cannabinoid-based medicine by asking patients who used cannabis or cannabinoids detailed questions about their experiences with different methods of intake. The survey was completed by 953 participants from 31 countries, making this the largest international survey on a wide variety of users of cannabinoid-based medicine performed so far. In general, herbal non-pharmaceutical CBMs received higher appreciation scores by participants than pharmaceutical products containing cannabinoids. However, the number of patients who reported experience with pharmaceutical products was low, limiting conclusions on preferences. Nevertheless, the reported data may be useful for further development of safe and effective medications based on cannabis and single cannabinoids.
Article
Full-text available
This minireview highlights the importance of cannabidiol (CBD) as a promising drug for the therapy of inflammatory bowel diseases (IBD). Actual pharmacological treatments for IBD should be enlarged toward the search for low-toxicityand low-cost drugs that may be given alone or in combination with the conventional anti-IBD drugs to increase their efficacy in the therapy of relapsing forms of colitis. In the past, Cannabis preparations have been considered new promising pharmacological tools in view of their anti-inflammatory role in IBD as well as other gut disturbances. However, their use in the clinical therapy has been strongly limited by their psychotropic effects. CBD is a very promising compound since it shares the typical cannabinoid beneficial effects on gut lacking any psychotropic effects. For years, its activity has been enigmatic for gastroenterologists and pharmacologists, but now it is evident that this compound may interact at extra-cannabinoid system receptor sites, such as peroxisome proliferator-activated receptor-gamma. This strategic interaction makes CBD as a potential candidate for the development of a new class of anti-IBD drugs. Copyright © 2012 John Wiley & Sons, Ltd.
Chapter
Full-text available
The Cannabis plant and its products consist of an enormous variety of chemicals. Some of the 483 compounds identified are unique to Cannabis, for example, the more than 60 cannabinoids, whereas the terpenes, with about 140 members forming the most abundant class, are widespread in the plant kingdom. The term “cannabinoids” [note: “ ” represents a group of C21 terpenophenolic compounds found until now uniquely in Cannabis sativa L. (1). As a consequence of the development of synthetic cannabinoids (e.g., nabilone [2], HU-211 [dexanabinol; ref. (3), or ajulemic acid [CT-3; ref. 4]) and the discovery of the chemically different endogenous cannabinoid receptor ligands (“endocannabinoids,” e.g., anandamide, 2-arachidonoylglycerol) (5,6), the term ’“phytocannabinoids’” was proposed for these particular Cannabis constituents (7).
Article
Full-text available
Cannabinoid receptor activation induces prostate carcinoma cell (PCC) apoptosis, but cannabinoids other than Δ9-tetrahydrocannabinol (THC), which lack potency at cannabinoid receptors, have not been investigated. Some of these compounds antagonize transient receptor potential melastatin type-8 (TRPM8) channels, the expression of which is necessary for androgen receptor (AR)-dependent PCC survival. We tested pure cannabinoids and extracts from Cannabis strains enriched in particular cannabinoids (BDS), on AR-positive (LNCaP and 22RV1) and -negative (DU-145 and PC-3) cells, by evaluating cell viability (MTT test), cell cycle arrest and apoptosis induction, by FACS scans, caspase 3/7 assays, DNA fragmentation and TUNEL, and size of xenograft tumours induced by LNCaP and DU-145 cells. Cannabidiol (CBD) significantly inhibited cell viability. Other compounds became effective in cells deprived of serum for 24 h. Several BDS were more potent than the pure compounds in the presence of serum. CBD-BDS (i.p.) potentiated the effects of bicalutamide and docetaxel against LNCaP and DU-145 xenograft tumours and, given alone, reduced LNCaP xenograft size. CBD (1–10 µM) induced apoptosis and induced markers of intrinsic apoptotic pathways (PUMA and CHOP expression and intracellular Ca2+). In LNCaP cells, the pro-apoptotic effect of CBD was only partly due to TRPM8 antagonism and was accompanied by down-regulation of AR, p53 activation and elevation of reactive oxygen species. LNCaP cells differentiated to androgen-insensitive neuroendocrine-like cells were more sensitive to CBD-induced apoptosis. These data support the clinical testing of CBD against prostate carcinoma. LINKED ARTICLE This article is commented on by Pacher et al., pp. 76–78 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476-5381.2012.02121.x
Article
Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) [Sativex(®)] is an oromucosal spray formulation that contains principally THC and CBD at an approximately 1:1 fixed ratio, derived from cloned Cannabis sativa L. plants. The main active substance, THC, acts as a partial agonist at human cannabinoid receptors (CB1 and CB2), and thus, may modulate the effects of excitatory (glutamate) and inhibitory (gamma-aminobutyric acid) neurotransmitters. THC/CBD is approved in a number of countries, including Germany and the UK, as an add-on treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy. In the largest multinational clinical trial that evaluated the approved THC/CBD regimen in this population, 12 weeks' double-blind treatment with THC/CBD significantly reduced spasticity severity (primary endpoint) compared with placebo in patients who achieved a clinically significant improvement in spasticity after 4 weeks' single-blind THC/CBD treatment, as assessed by a patient-rated numerical rating scale. A significantly greater proportion of THC/CBD than placebo recipients achieved a ≥30 % reduction (a clinically relevant reduction) in spasticity severity. The efficacy of THC/CBD has been also shown in at least one everyday clinical practice study (MOVE 2). THC/CBD was generally well tolerated in clinical trials. Dizziness and fatigue were reported most frequently during the first 4 weeks of treatment and resolved within a few days even with continued treatment. Thus, add-on THC/CBD is a useful symptomatic treatment option for its approved indication.
Article
Background and purpose: Cannabis extracts and several cannabinoids have been shown to exert broad anti-inflammatory activities in experimental models of inflammatory CNS degenerative diseases. Clinical use of many cannabinoids is limited by their psychotropic effects. However, phytocannabinoids like cannabidiol (CBD), devoid of psychoactive activity, are, potentially, safe and effective alternatives for alleviating neuroinflammation and neurodegeneration. Experimental approach: We used experimental autoimmune encephalomyelitis (EAE) induced by myelin oligodendrocyte glycoprotein (MOG) in C57BL/6 mice, as a model of multiple sclerosis. Using immunocytochemistry and cell proliferation assays we evaluated the effects of CBD on microglial activation in MOG-immunized animals and on MOG-specific T-cell proliferation. Key results: Treatment with CBD during disease onset ameliorated the severity of the clinical signs of EAE. This effect of CBD was accompanied by diminished axonal damage and inflammation as well as microglial activation and T-cell recruitment in the spinal cord of MOG-injected mice. Moreover, CBD inhibited MOG-induced T-cell proliferation in vitro at both low and high concentrations of the myelin antigen. This effect was not mediated via the known cannabinoid CB(1) and CB(2) receptors. Conclusions and implications: CBD, a non-psychoactive cannabinoid, ameliorates clinical signs of EAE in mice, immunized against MOG. Suppression of microglial activity and T-cell proliferation by CBD appeared to contribute to these beneficial effects.